Your browser doesn't support javascript.
Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study.
Alattar, Rand A; Abdalla, Shiema; Abdallah, Tasneem; Kazman, Rashid; Qadmour, Aseelah; Ibrahim, Tawheeda; Alhariri, Bassem; Shaar, Shahd H; Bajwa, Abeer; Alimam, Abeir; Qazi, Rabia; Ben Abid, Fatma; Daghfal, Joanne; Eldeeb, Ali; Shukri, Kinda; Elsayed, Ahmed; Rustom, Fatima; Alsamawi, Musaed; Abdelmajid, Alaaeldin; Basulto, Miguel A P; Cobian, Armando A R; Abukhattab, Mohamed; Alkhal, Abdullatif; Almaslamani, Muna A; Omrani, Ali S.
  • Alattar RA; Communicable Disease Center, Hamad Medical Corporation.
  • Abdalla S; Communicable Disease Center, Hamad Medical Corporation.
  • Abdallah T; Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Kazman R; Division of Internal Medicine, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Qadmour A; Division of Internal Medicine, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Ibrahim T; Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Alhariri B; Division of Internal Medicine, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Shaar SH; Communicable Disease Center, Hamad Medical Corporation.
  • Bajwa A; Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Alimam A; Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Qazi R; Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Ben Abid F; Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Daghfal J; Communicable Disease Center, Hamad Medical Corporation.
  • Eldeeb A; Department of Clinical Imaging, Hamad Medical Corporation, Doha, Qatar.
  • Shukri K; Department of Clinical Imaging, Hamad Medical Corporation, Doha, Qatar.
  • Elsayed A; Communicable Disease Center, Hamad Medical Corporation.
  • Rustom F; Communicable Disease Center, Hamad Medical Corporation.
  • Alsamawi M; Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Abdelmajid A; Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Basulto MAP; Cuban Hospital, Dukhan, Qatar.
  • Cobian AAR; Cuban Hospital, Dukhan, Qatar.
  • Abukhattab M; Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Alkhal A; Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Almaslamani MA; Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
  • Omrani AS; Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar; Faculty of Medicine, Qatar University. Electronic address: aomrani@hamad.qa.
J Infect Public Health ; 15(10): 1061-1064, 2022 Aug 27.
Article in English | MEDLINE | ID: covidwho-2004244
ABSTRACT
We retrospectively investigated the clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Patients who between 23 May 2020 and 18 July 2020 received ≥ 24 h of favipiravir were assigned to the favipiravir group, while those who did not formed the non-favipiravir group. The primary outcome was 28-day clinical improvement, defined as two-category improvement from baseline on an 8-point ordinal scale. Propensity scores (PS) for favipiravir therapy were used for 11 matching. The unmatched cohort included 1493 patients, of which 51.7% were in the favipiravir group, and 48.3% were not receiving supplemental oxygen at baseline. Significant baseline differences between the two unmatched groups existed, but not between the PS-matched groups (N = 774). After PS-matching, there were no significant differences between the two groups in the proportion with 28-day clinical improvement (93.3% versus 92.8%, P 0.780), or 28-day all-cause mortality (2.1% versus 3.1%, P 0.360). Favipiravir was associated with more viral clearance by day 28 (79.8% versus 64.1%, P < 0.001). Adverse events were common in both groups, but the 93.9% were Grades 1-3. Favipiravir therapy for COVID-19 pneumonia is well tolerated but is not associated with an increased likelihood of clinical improvement or reduced all-cause mortality by 28 days.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: J Infect Public Health Journal subject: Communicable Diseases / Public Health Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: J Infect Public Health Journal subject: Communicable Diseases / Public Health Year: 2022 Document Type: Article